MA33834B1 - Formulation contenant des antagonistes du récepteur ampa à base de 1h-quinazoline-2,4-dione, sous la forme de comprimés à libération immédiate et leur préparation - Google Patents

Formulation contenant des antagonistes du récepteur ampa à base de 1h-quinazoline-2,4-dione, sous la forme de comprimés à libération immédiate et leur préparation

Info

Publication number
MA33834B1
MA33834B1 MA34983A MA34983A MA33834B1 MA 33834 B1 MA33834 B1 MA 33834B1 MA 34983 A MA34983 A MA 34983A MA 34983 A MA34983 A MA 34983A MA 33834 B1 MA33834 B1 MA 33834B1
Authority
MA
Morocco
Prior art keywords
substituents
group
chosen
amino
dialkylamino
Prior art date
Application number
MA34983A
Other languages
Arabic (ar)
English (en)
Inventor
Joseph Lawrence Zielinski
John Vrettos
Qin Ji
Subash Patel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43610748&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33834(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MA33834B1 publication Critical patent/MA33834B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un comprimé contenant une hydroxypropylcellulose et un principe actif choisi parmi des composés de formule (i) et leurs sels : où r1 représente un groupe cf3, chf2, ch2f, ch3chf-, ch3cf2-, éthyle ou iso-propyle et r2 représente un groupe alkyle substitué par un ou plusieurs substituants, les substituants étant choisis dans le groupe comprenant les atomes d'halogène, les groupes nitro, cyano, acyle, hydroxy, oxo (=o), alcoxy, cycloalcoxy, acyloxy, alcoxycarbonyloxy, amino, alkylamino, dialkylamino, formyle, acylamino, alcoxycarbonylamino ou r2 représente un groupe hétérocyclylalkyle substitué par un ou plusieurs substituants, les substituants étant choisis dans le groupe comprenant les atomes d'halogène, les groupes nitro, cyano, hydroxy, alcoxy, alkylcarbonyloxy, alcoxycarbonyloxy, amino, alkylamino, dialkylamino, alcoxycarbonylamino, ou r2 représente un groupe phényle substitué par un ou plusieurs substituants, les substituants étant choisis dans le groupe comprenant les groupes cyano, hydroxy, alcanediyle, alcènediyle, alcoxy, hydroxyalkyle, formyle, alkylcarbonyle, alcoxycarbonyle, alkylcarbonyloxy, alcoxycarbonyloxy, amino, alkylamino, dialkylamino, aminoalkyle, alkylaminoalkyle, dialkylaminoalkyle, alcoxycarbonylamino, ou r2 représente un groupe hétérocyclyle éventuellement substitué par un ou plusieurs substituants, les substituants étant choisis dans le groupe comprenant les atomes d'halogène, les groupes hydroxy, amino, nitro, cyano, alkyle, hydroxyalkyle, alcoxyalkyle, aminoalkyle, alkylaminoalkyle, dialkylaminoalkyle, acyle, alcoxy, acyloxy, alcoxycarbonyloxy, amino, alkylamino, dialkylamino, acylamino, alcoxycarbonylamino et l'hétérocycle étant lié au cycle phényle par un atome de carbone. L'invention a également pour objet un procédé de préparation du comprimé ci-dessus.
MA34983A 2009-12-22 2012-06-18 Formulation contenant des antagonistes du récepteur ampa à base de 1h-quinazoline-2,4-dione, sous la forme de comprimés à libération immédiate et leur préparation MA33834B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28898509P 2009-12-22 2009-12-22
PCT/US2010/061553 WO2011079119A1 (fr) 2009-12-22 2010-12-21 Formulation contenant des antagonistes du récepteur ampa à base de 1h-quinazoline-2,4-dione, sous la forme de comprimés à libération immédiate et leur préparation

Publications (1)

Publication Number Publication Date
MA33834B1 true MA33834B1 (fr) 2012-12-03

Family

ID=43610748

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34983A MA33834B1 (fr) 2009-12-22 2012-06-18 Formulation contenant des antagonistes du récepteur ampa à base de 1h-quinazoline-2,4-dione, sous la forme de comprimés à libération immédiate et leur préparation

Country Status (19)

Country Link
US (1) US20120263791A1 (fr)
EP (1) EP2515873A1 (fr)
JP (1) JP2013515076A (fr)
KR (1) KR20120105035A (fr)
CN (2) CN104013587A (fr)
AU (1) AU2010336510B2 (fr)
BR (1) BR112012016920A2 (fr)
CA (1) CA2784996A1 (fr)
CL (1) CL2012001689A1 (fr)
EC (1) ECSP12011994A (fr)
GT (1) GT201200209A (fr)
MA (1) MA33834B1 (fr)
MX (1) MX2012007320A (fr)
NZ (1) NZ600717A (fr)
PE (1) PE20121394A1 (fr)
RU (1) RU2012131051A (fr)
SG (1) SG181787A1 (fr)
WO (1) WO2011079119A1 (fr)
ZA (1) ZA201204607B (fr)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2465693A1 (fr) * 2003-06-12 2004-12-12 Warner-Lambert Company Llc Compositions pharmaceutiques d'atorvastatine
GB0416730D0 (en) * 2004-07-27 2004-09-01 Novartis Ag Organic compounds
GB0507298D0 (en) * 2005-04-11 2005-05-18 Novartis Ag Organic compounds
CA2604735A1 (fr) * 2005-04-12 2006-10-19 Elan Pharma International Limited Formules de nanoparticules de derives de quinazoline
JOP20180109A1 (ar) * 2005-09-29 2019-01-30 Novartis Ag تركيبة جديدة
EP1968553A2 (fr) * 2005-11-09 2008-09-17 Novartis AG Procede de fabrication de compositions pharmaceutiques utilisant un plastifiant transitoire
KR20100121483A (ko) * 2008-02-11 2010-11-17 다이닛본 스미토모 세이야꾸 가부시끼가이샤 용출성이 개선된 정제

Also Published As

Publication number Publication date
SG181787A1 (en) 2012-07-30
ZA201204607B (en) 2013-02-27
WO2011079119A1 (fr) 2011-06-30
JP2013515076A (ja) 2013-05-02
AU2010336510B2 (en) 2014-06-26
US20120263791A1 (en) 2012-10-18
AU2010336510A1 (en) 2012-07-12
BR112012016920A2 (pt) 2016-04-12
ECSP12011994A (es) 2012-07-31
RU2012131051A (ru) 2014-01-27
NZ600717A (en) 2014-06-27
GT201200209A (es) 2013-09-09
MX2012007320A (es) 2012-07-20
CA2784996A1 (fr) 2011-06-30
PE20121394A1 (es) 2012-10-29
CL2012001689A1 (es) 2013-01-11
KR20120105035A (ko) 2012-09-24
CN104013587A (zh) 2014-09-03
CN102770124A (zh) 2012-11-07
EP2515873A1 (fr) 2012-10-31

Similar Documents

Publication Publication Date Title
MA45222A (fr) Nouveaux dérivés de pipéridinyle, procédé de préparation de ceux-ci et compositions pharmaceutiques les contenant
MA38138A1 (fr) Dérivés inédits de quinolone
PE20130385A1 (es) Derivados del acido naft-2-ilacetico para tratar el sida
MA37405A1 (fr) Composés hétérocyclyle
CA2536136A1 (fr) Imidazoquinolines substituees par aryloxy et arylalkyleneoxy
KR910006218A (ko) 2-아미도테트라린 치환유도체와 이 치환유도체를 포함하는 제약학적 조성물 및 이를 사용한 치료방법
JP2972377B2 (ja) カテコール誘導体、その薬学的に許容しうる塩およびエステルならびにそれらを含有する医薬組成物
RU2010126105A (ru) Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой, и содержащие их противогрибковые средства
MA37891A1 (fr) Alcoxypyrazoles comme activateurs de guanylate cyclase soluble
RU2011131276A (ru) 1н-хиназолин-2,4-дионы
JP2018500388A (ja) 代謝疾患及び癌の治療のための、新規ミトコンドリアアンカップラー
MA31674B1 (fr) Dérivés de 7 -alkynyl-1,8-naphthyridones, leur préparation et leur application en thérapeutique
IE83426B1 (en) New pharmacologically active catechol derivatives
MA32057B1 (fr) Derives d'imtoazo [1,2-a] pyridine-2-carboxamides,leur préparation et leur application en thérapeutique
TN2010000025A1 (fr) Derives de l'indol -2-one disubstitues en 3, leur preparation et leur application en therapeutique
RU2012126112A (ru) Соединение, некоторые его новые формы, фармацевтические композиции на его основе и способы получения и применения
AU2016214283B2 (en) Compounds with anti-tumoral activity
RU2010143586A (ru) Новое производное тетрагидроизохинолина
MA29961B1 (fr) Derives de 6-heteroarylpyridoindolone, leur preparation et leur application en therapeutique
AU2014413483A1 (en) 7-(morpholinyl)-2-(N-piperazinyl) methyl thieno [2, 3-c] pyridine derivatives as anticancer drugs
MA33834B1 (fr) Formulation contenant des antagonistes du récepteur ampa à base de 1h-quinazoline-2,4-dione, sous la forme de comprimés à libération immédiate et leur préparation
EP1219605A4 (fr) Composes d'uree, procede de production et d'utilisation de ces derniers
TN2015000240A1 (fr) Derives d'aminocyclobutane, leur procede de preparation et leur utilisation a titre de medicaments
FR2941947B1 (fr) Derives de 3-benzofuranyl-indol-2-one subtitues en 3, leur preparation et leur application en therapeutique
KR870010043A (ko) 헤테로고리로 치환된 벤즈이미다졸, 그의 제조방법 및 이들을 함유하는 제약조성물